{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:32:46Z","timestamp":1789014766242,"version":"build-2803163510"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T00:00:00Z","timestamp":1442016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Vincristine is an antimitotic agent used for treatment of leukemia, lymphomas, and cancers. Its main side effect is a dose\u2010related, length\u2010dependent (LD) axonal neuropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed electrodiagnostic (EDx) examinations in 17 children who had been treated with vincristine and who presented with the clinical picture of a peripheral neuropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean dose of vincristine was 8.5\u2009\u00b1\u20094.0 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . Clinical motor symptoms were more frequent and more severe than sensory ones. Thirteen children presented with a motor deficit, 4 of whom could no longer walk. EDx examination showed an axonal neuropathy with a non\u2013length\u2010dependent (NLD) pattern in 9 children and an LD pattern in 8. A major motor predominance was encountered in 12 patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The electrophysiological and clinical motor predominance described differs from the mainly sensory neuropathy reported in adults. Incomplete myelination due to young age may have resulted in greater sensitivity of some nerves to neurotoxic agents.\n                      <jats:italic>Muscle Nerve<\/jats:italic>\n                      <jats:bold>52<\/jats:bold>\n                      : 981\u2013985, 2015\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mus.24647","type":"journal-article","created":{"date-parts":[[2015,3,10]],"date-time":"2015-03-10T20:43:08Z","timestamp":1426020188000},"page":"981-985","source":"Crossref","is-referenced-by-count":39,"title":["Vincristine\u2010induced neuropathy: Atypical electrophysiological patterns in children"],"prefix":"10.1002","volume":"52","author":[{"given":"H\u00e9l\u00e8ne","family":"Courtemanche","sequence":"first","affiliation":[{"name":"Laboratoire d'Explorations Fonctionnelles H\u00f4tel\u2010Dieu, CHU de Nantes 44093 Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Magot","sequence":"additional","affiliation":[{"name":"Laboratoire d'Explorations Fonctionnelles H\u00f4tel\u2010Dieu, CHU de Nantes 44093 Nantes France"},{"name":"Centre de R\u00e9f\u00e9rence Maladies Neuromusculaires Nantes Angers CHU de Nantes Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolaine","family":"Ollivier","sequence":"additional","affiliation":[{"name":"Laboratoire d'Explorations Fonctionnelles H\u00f4tel\u2010Dieu, CHU de Nantes 44093 Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Rialland","sequence":"additional","affiliation":[{"name":"Service d'Oncologie P\u00e9diatrique H\u00f4pital M\u00e8re\u2010Enfant CHU de Nantes Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laur\u00e8ne","family":"Leclair\u2010Visonneau","sequence":"additional","affiliation":[{"name":"Laboratoire d'Explorations Fonctionnelles H\u00f4tel\u2010Dieu, CHU de Nantes 44093 Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillemette","family":"Fayet","sequence":"additional","affiliation":[{"name":"Laboratoire d'Explorations Fonctionnelles H\u00f4tel\u2010Dieu, CHU de Nantes 44093 Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Philippe","family":"Camdessanch\u00e9","sequence":"additional","affiliation":[{"name":"Service de Neurologie CHU de Saint\u2010Etienne Saint\u2010Etienne France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"P\u00e9r\u00e9on","sequence":"additional","affiliation":[{"name":"Laboratoire d'Explorations Fonctionnelles H\u00f4tel\u2010Dieu, CHU de Nantes 44093 Nantes France"},{"name":"Centre de R\u00e9f\u00e9rence Maladies Neuromusculaires Nantes Angers CHU de Nantes Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,12]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"3798","article-title":"Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro","volume":"36","author":"Himes RH","year":"1976","journal-title":"Cancer Res"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(80)90179-3"},{"key":"e_1_2_6_4_1","first-page":"107","article-title":"The neuromyopathy of vincristine in man","volume":"10","author":"Bradley WG","year":"1970","journal-title":"Clinical, electrophysiological and pathological studies. J Neurol Sci"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.32.4.297"},{"key":"e_1_2_6_6_1","first-page":"69","article-title":"Vincristine neuropathy","volume":"96","author":"Casey EB","year":"1973","journal-title":"Clinical and electrophysiological observations. Brain"},{"key":"e_1_2_6_7_1","first-page":"367","article-title":"Vincristine\u2010induced neuropathy","volume":"19","author":"Sandler SG","year":"1969","journal-title":"A clinical study of fifty leukemic patients. Neurology"},{"key":"e_1_2_6_8_1","first-page":"1258","article-title":"Vincristine treatment of advanced cancer: a cooperative study of 392 cases","volume":"33","author":"Holland JF","year":"1973","journal-title":"Cancer Res"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-013-9751-6"},{"key":"e_1_2_6_10_1","first-page":"583","article-title":"Low\u2010dose vincristine\u2010associated bilateral vocal cord paralysis","volume":"63","author":"Ryan SP","year":"1999","journal-title":"Conn Med"},{"key":"e_1_2_6_11_1","first-page":"138","article-title":"Evaluation of neuropathy during intensive vincristine chemotherapy for non\u2010Hodgkin's lymphoma and acute lymphoblastic leukemia","volume":"3","author":"Dorchin M","year":"2013","journal-title":"Iran J Ped Hematol Oncol"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neucli.2004.04.005"},{"key":"e_1_2_6_13_1","first-page":"323","article-title":"Clinical and electrophysiological studies in vincristine induced neuropathy","volume":"39","author":"Pal PK","year":"1999","journal-title":"Electromyogr Clin Neurophysiol"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-009-0254-3"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073813491829"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2009.00230.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/ejpn.1999.0310"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.25.9.894"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009054898"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181e01584"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2005.11.014"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008469-200404000-00002"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-3787(06)75145-1"},{"key":"e_1_2_6_24_1","first-page":"18","article-title":"Chemotherapy\u2010induced neurotoxicity: the value of neuroprotective strategies","volume":"70","author":"Beijers AJM","year":"2012","journal-title":"Neth J Med"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.24647","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.24647","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.24647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T05:05:09Z","timestamp":1696568709000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.24647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1002\/mus.24647"],"URL":"https:\/\/doi.org\/10.1002\/mus.24647","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,12]]}}}